97210 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER
#2ANTI-FUCOSYL-GM1 ANTIBODY DRUG CONJUGATES
#3IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
#4PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER
#5A MULTIPLEXED RNA REGULATION PLATFORM FOR PRIMARY IMMUNE CELL ENGINEERING
#6GD2 BI-SPECIFIC INVARIANT NATURAL KILLER T CELL ENGAGERS AND METHODS OF USE THEREOF
#7HUMAN MONOCLONAL ANTIBODIES TO FUCOSYL-GM1 AND METHODS FOR USING ANTI-FUCOSYL-GM1 ANTIBODIES
#8Compositions and Methods for Inhibiting T Cell Exhaustion
#9ADENO-ASSOCIATED VIRUS VECTORS AND METHODS OF THEIR USE FOR REDUCING THE RISK OF, TREATING, AND PREVENTING METASTASIS
#10Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof
#11MULTISPECIFIC BINDING AGENTS THAT TARGET B7H3 AND GD2 AND USES THEREOF
#12PSMA BINDING ANTIBODY AND USES THEREOF
#13PURIFYING ANTIBODIES
#14COMPOSITIONS AND METHODS FOR UPREGULATING HLA CLASS I ON TUMOR CELLS
#15MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES
#16COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS
#17VIRUS-FREE CRISPR CAR NATURAL KILLER CELLS
#18FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT
#19Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#20ANTI-GD2 ANTIBODIES, IMMUNOCONJUGATES AND THERAPEUTIC USES THEREOF
#21TREATMENT OF CANCERS WITH A REGIMEN OF TARGETED RADIONUCLIDE THERAPY AND DUAL CAR T CELL THERAPY
#22METHODS AND COMPOSITIONS FOR TREATING CANCER
#23GD2 CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
#24NATURAL KILLER T-CELLS AND METHODS OF USING THE SAME
#25METHODS FOR TREATING NEUROBLASTOMA
#26COMPOSITIONS AND METHODS FOR TREATING CANCER
#27scFv and Antibodies with Reduced Multimerisation
#28Formulations Comprising a SADA Complex
#29MIR155 AS THE INTEGRATION SITE TO OVERCOME ACUTE GRAFT VERSUS HOST DISEASE OF GENE-MODIFIED IMMUNE EFFECTOR CELLS
#30DUAL TARGETING OF PEDIATRIC MALIGNANCIES THROUGH CAR T-CELLS SECRETING BISPECIFIC INNATE IMMUNE CELL ENGAGERS (BICES)
#31NATURAL KILLER CELL-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
#32Improved Antibody Masking Domains
#33CHIMERIC FC-ALPHA RECEPTORS AND USES THEREOF
#34FUSION PROTEIN TARGETING BOTH CD3 AND CD137, PREPARATION METHOD THEREFOR AND USE THEREOF
#35Antibody Masking Domains
#36MODULAR SYNTHETIC RECEPTORS AND METHODS OF USE
#37NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME
#38CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS
#39CHIMERIC ANTIGEN RECEPTOR
#40Methods of Treating T Cell Exhaustion by Inhibiting or Modulating T Cell Receptor Signaling
#41Compositions And Methods For Enhancing Immunotherapy
#42MULTISPECIFIC ANTIBODIES BINDING TO TUMOR-ASSOCIATED ANTIGENS CAUSING NO OR REDUCED NERVE PAIN IN THE TREATMENT OF CANCER
#43NEW METHOD TO IMPROVE NK CELLS CYTOTOXICITY
#44ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
#45Anti-GM2AP ANTIBODY AND APPLICATIONS THEREOF
#46MUTATED FERRITIN PROTEIN
#47BI-SPECIFIC ANTIBODIES FOR USE IN PRODUCING ARMED IMMUNE CELLS
#48Dimeric Antigen Receptors (DARs) that Bind GD2
#49NEW METHOD TO IMPROVE THE ANTI-TUMORAL ACTIVITY OF MACROPHAGES
#50METHODS FOR TREATING NEUROBLASTOMA
#51PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER
#52COMBINATIONAL IMMUNOTHERAPIES USING CAR-M, CAR-NK, CAR-EOS, AND CAR-N CELLS
#53UNIVERSAL CAR-T CELL TARGETING GD2, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
#54ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
#55HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2
#56CHIMERIC ANTIGEN RECEPTOR FUSION PROTEIN CO-EXPRESSING IL-7 AND CCR2B, AND APPLICATION THEREOF
#57RECOMBINANT ANTIBODIES, KITS COMPRISING THE SAME, AND USES THEREOF
#58Engineered NKT Cells for Expansion and In Vivo Preservation and Methods of Use for the Control of Tumor Cells
#59DUAL TARGETING CHIMERIC ANTIGEN RECEPTORS
#60RECOMBINANT POLYPEPTIDES FOR REGULATABLE CELLULAR LOCALIZATION
#61LIGHT CHAIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE THEREOF
#62Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination
#63ANTIGEN RECOGNIZING RECEPTORS TARGETING GD3 GANGLIOSIDE AND USES THEREOF
#64CARBOHYDRATE STRUCTURES AND USES THEREOF
#65NUCLEIC ACID CONSTRUCTS AND CELLS
#66METHODS FOR TREATING CANCER WITH ANTI-GD2/GD3 ANTIBODIES
#67USE OF ANTIBODY AGAINST O-ACETYLATED GD2 GANGLIOSIDE TO IMPROVE THE THERAPEUTIC POTENTIAL OF DRUGS
#68Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#69Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof
#70METHOD FOR TREATING A GD2 POSITIVE CANCER
#71Glycan-Interacting Compounds and Methods of Use
#72Human otic progenitor identification and isolation
#73METHOD FOR TREATING A GD2-POSITIVE CANCER
#74COMBINATION THERAPY FOR TREATING OR PREVENTING CANCER
#75ANTI-GD2 SADA CONJUGATES AND USES THEREOF
#76MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES
#77HUMANIZED ANTIBODY AGAINST O-ACETYLATED GD2 GANGLIOSIDE (OACGD2)
#78GLYPICAN-2-BINDING MOIETIES, CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#79PSMA Binding Antibody and Uses Thereof
#80USE OF ANTIBODY DRUG CONJUGATES COMPRISING TUBULIN DISRUPTING AGENTS TO TREAT SOLID TUMOR
#81MULTIMODAL FLUORINE-CY3/5/7-DOTA-HAPTEN COMPOSITIONS, DIAGNOSTICS, FLUORESCENCE GUIDED SURGERY AND RADIOIMMUNOTHERAPY
#82COMPOSITIONS AND METHODS FOR TREATMENT OF CANCERS HARBORING AN H3K27M MUTATION
#83FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT
#84Bispecific GD2 and B7H3 Binding Molecules and Methods of Use
#85COMPOSITIONS AND METHODS FOR UPREGULATING HLA CLASS I ON TUMOR CELLS
#86HUMAN MONOCLONAL ANTIBODIES TO FUCOSYL-GM1 AND METHODS FOR USING ANTI-FUCOSYL-GM1 ANTIBODIES
#87Compositions and Methods for Inhibiting T Cell Exhaustion
#88FUSION PROTEINS WITH ARGINASE ACTIVITY
#89CAR NKTs Expressing Artificial Micro RNA-Embedded shRNA for Downregulation of MHC Class I & II Expression
#90COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
#91NOVEL RECEPTORS HAVING A FIBRONECTIN REPEAT FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION
#92SSEA-4 BINDING MEMBERS
#93GD2 BINDING MOLECULE
#94ANTI-FUCOSYL-GM1 ANTIBODIES
#95Glycan-Interacting Compounds and Methods of Use
#96TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY
#97CHIMERIC ANTIGEN RECEPTOR COMPRISING INTERLEUKIN-15 INTRACELLULAR DOMAIN AND USES THEREOF
#98HETERODIMERIC TETRAVALENCY AND SPECIFICITY ANTIBODY COMPOSITIONS AND USES THEREOF
#99IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
#100Chimeric antigen receptor
#101METHODS FOR TREATING NEUROBLASTOMA
#102Modular synthetic receptors and methods of use
#103GD2-based chimeric antigen receptor and application thereof
#104METHOD FOR THE PRODUCTION OF BI-FUNCTIONAL CELLS TO TREAT NEOPLASIA
#105Preparations and methods for treating a GD2 positive cancer
#106METHODS FOR TREATING NEUROBLASTOMA WITH COMBINATION THERAPY
#107Human monoclonal antibodies to ganglioside GD2
#108Compositions And Methods For Enhancing Immunotherapy
#109ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA
#110IL-15 and IL-15R\alpha sushi domain based immunocytokines
#111METHOD FOR PURIFYING ANTIBODIES
#112Compositions and methods for treatment of cancers harboring an H3K27M mutation
#113CHIMERIC ANTIGEN RECEPTOR
#114COMBINATION THERAPY FOR TREATING OR PREVENTING CANCER
#115Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling
#116PROCESS FOR PRODUCING HU14.18K322A MONOCLONAL ANTIBODY
#117IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
#118Preparations and methods for treating a GD2 positive cancer
#119Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
#120Anti-GD2 antibody
#121TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER (PINK) CELLS IN COMBINATION WITH AN ANTIBODY
#122PROTEINS BINDING GD2, NKG2D AND CD16
#123NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
#124Modular self assembly disassembly (SADA) technologies
#125ANTIBODIES, BINDING FRAGMENTS, AND METHODS OF USE
#126METHODS OF TREATING T CELL EXHAUSTION BY INHIBITING OR MODULATING T CELL RECEPTOR SIGNALING
#127Method for Treating a GD2 Positive Cancer
#128METHOD OF PRODUCING ANTIBODIES WITH N-GLYCOSIDE-LINKED SUGAR CHAINS LACKING FUCOSYLATION
#129TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY
#130Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
#131Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof
#132Car t-cells comprising inactivated CBL and CBL-B genes
#133ANTIBODY COMPOSITION-PRODUCING CELL
#134Carbohydrate structures and uses thereof
#135Genetically modified veto cells and use of same in immunotherapy
#136METHOD FOR PURIFYING ANTIBODIES USING PBS
#137HUMAN MONOCLONAL ANTIBODIES TO FUCOSYL-GM1 AND METHODS FOR USING ANTI-FUCOSYL-GM1 ANTIBODIES
#138MODIFIED ANTIGEN-BINDING FAB FRAGMENTS AND ANTIGEN-BINDING MOLECULES COMPRISING THE SAME
#139Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor
#140Humanized antibody against O-acetylated GD2 ganglioside (OAcGD2)
#141Human otic progenitor identification and isolation
#142Compositions and methods for inhibiting T cell exhaustion
#143Eliminating MHC restriction from the T cell receptor as a strategy for immunotherapy
#144Anti-cancer antibodies with reduced complement fixation
#145Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer
#146PSMA binding antibody and uses thereof
#147Human monoclonal antibodies to ganglioside GD2
#148Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
#149Glycan-interacting compounds and methods of use
#150IL-15 and IL-15Rα sushi domain based immunocytokines
#151Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
#152Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
#153NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
#154Preparations and methods for treating a GD2 positive cancer
#155MULTIMERIZATION TECHNOLOGIES
#156Recombinant human IgM-antibody effective against cancer cells
#157DE-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#158Chimeric antigen receptors and uses thereof
#159Method for treating a GD2 positive cancer
#160CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY
#161Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
#162NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR
#163USE OF CAR-MODIFIED HUMAN NATURAL KILLER CELLS TO TREAT CANCER
#164Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
#165CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY
#166Anti-GD2 antibodies
#167TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY
#168METHOD OF MODULATING THE ACTIVITY OF FUNCTIONAL IMMUNE MOLECULES
#169Anti-cancer antibodies with reduced complement fixation
#170HUMAN MONOCLONAL ANTIBODIES TO FUCOSYL-GM1 AND METHODS FOR USING ANTI-FUCOSYL-GM1 ANTIBODIES
#171FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
#172Chimeric antigen receptor
#173IMMUNOTHERAPY OF CANCER USING GENETICALLY ENGINEERED GD2-SPECIFIC T CELLS
#174Antibody composition-producing cell
#175IL-15 and IL-15R\alpha sushi domain based immunocytokines
#176NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
#177Preparations and methods for treating a GD2 positive cancer
#178Anti-ganglioside compound for targeting cancer and generating antibodies
#179Method for purifying antibodies
#180Human IgG1 derived antibody with pro-apoptotic activity
#181Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides
#182Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
#183Method for purifying antibodies using PBS
#184DE-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#185Anti-GD2 antibodies
#186Antibody multimerization technologies
#187Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
#188High affinity anti-GD2 antibodies
#189Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 antibodies
#190Human monoclonal antibodies to ganglioside GD2
#191Recombinant human IgM-antibody effective against cancer cells
#192AN IL-15 AND IL-15R\alpha SUSHI DOMAIN BASED IMMUNOCYTOKINES
#193Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
#194Chimeric receptors and uses thereof in immune therapy
#195Method for treating a GD2 positive cancer
#196Antibody composition-producing cell
#197Recombinant antibodies having dual specificity for gangliosides and use thereof
#198Anti-cancer antibodies with reduced complement fixation
#199Ganglioside GD2 as a marker and target on cancer stem cells
#200Pharmaceutical compositions for the treatment of tumors expressing EGFR and GM3 N-glycolyl ganglioside (NeuGcGM3)
#201Targeted carriers for drug delivery across the gastrointestinal epithelium
#202Modified effector cell (or chimeric receptor) for treating disialoganglioside G-expressing neoplasia
#203Light chain immunoglobulin fusion proteins and methods of use thereof
#204Method of modulating the activity of functional immune molecules
#205Method for treating a GD2 positive cancer
#206Antibody for 3′-isoLM1 and 3′,6′-iso-LD1 gangliosides
#207Cells expressing anti-GD2 antibodies and methods related thereto
#208Anti-GD2 antibodies
#209Antibody composition-producing cell
#210Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1 antibodies
#211Anti-GD2 antibodies
#212Ganglioside epitopes for treating Guillain-Barre syndrome
#213Anti ganglioside GD3 antibodies and uses thereof
#214Targeted carriers for drug delivery across the gastrointestinal epithelium
#215De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#216SUPERANTIBODY SYNTHESIS AND USE IN DETECTION, PREVENTION AND TREATMENT OF DISEASE
#217AUTOPHILIC ANTIBODIES AND METHOD OF MAKING THE SAME
#218Antibody composition-producing cell
#219Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
#220Ganglioside epitopes for treating guillain-barre syndrome
#221Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody
#222Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation
#223ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION
#224Uses of monoclonal antibody 8H9
#225Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
#226Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors
#227ANTIBODY HAVING INHIBITORY EFFECT ON AMYLOID FIBRIL FORMATION
#228De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#229Novel Ligand Involved In The Transmigration Of Leukocytes Across the Endothelium and Uses Therefor
#230Method for preparation of single chain antibodies
#231Immunocytokine sequences and uses thereof
#232Method of modulating the activity of functional immune molecules
#233Destruction of tumor cells by trifunctional bispecific antibodies with low to medium expression levels of tumor-associated target antigens
#234CRYPTIC GLYCAN MARKERS AND APPLICATIONS THEREOF
#235Anti-ganglioside antibodies and compositions
#236CANCER THERAPY USING WHOLE GLUCAN PARTICLES AND ANTIBODIES
#237Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for treatment of certain cancers
#238Antibody Composition-Producing Cell
#239BIFUNCTIONAL FUSION MOLECULES FOR THE DELIVERY OF ANTIGENS TO PROFESSIONAL ANTIGEN-PRESENTING CELLS
#240PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY COMPOSITION WHICH SPECIFICALLY BINDS TO GANGLIOSIDE GM2
#241PHARMACEUTICAL COMPOSITION
#242Method of enhancing of binding activity of antibody composition to Fcγ receptor IIIa
#243Anti ganglioside GD3 antibodies and uses thereof
#244Polynucleotides encoding anti-GD2 antibodies
#245Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain
#246AUTOPHILIC ANTIBODIES AND METHOD OF MAKING THE SAME
#247Highly concentrated stabilized IgM solution
#248Chimeric antibody against tumor associated antigens and its use in diagnosing tumors
#249Cells with altered fucosylation and producing antibodies therefrom
#250SUPERANTIBODY SYNTHESIS AND USE IN DETECTION, PREVENTION AND TREATMENT OF DISEASE
#251Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation
#252Glycoengineered, recombinant antibody
#253Anti-cancer antibodies with reduced complement fixation
#254Antibody having inhibitory effect on amyloid fibril formation
#255IMMUNE RESPONSE ENHANCING GLUCAN
#256Antibody Composition Specifically Binding to Ganglioside Gm
#257Therapy-enhancing glucan
#258Antibody composition-producing cell in which enzyme expression is inhibited by RNAi
#259Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase
#260Method of modulating the activity of functional immune molecules
#261Method for Improved Transgene Expression
#262Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
#263Methods of targeting multiple cytokines
#264Highly Concentrated Stabilized Igm Solution
#265Method of modulating the activity of functional immune molecules to platelet-derived growth factor receptor
#266Method of modulating the activity of functional immune molecules to Her-2
#267Method of modulating the activity of functional immune molecules to CD52
#268Method of modulating the activity of functional immune molecules to GM2
#269Method of modulating the activity of functional immune molecules to CXCR4 protein
#270Method of modulating the activity of functional immune molecules
#271Method of modulating the activity of functional immune molecules to interleukin-5 receptor protein
#272Polynucleotides encoding anti-ganglioside antibodies
#273Process for producing humanized chimera antibody
#274Method of isolating cytotoxic heterocomplex associated with multiple sclerosis
#275Immunocytokine sequences and uses thereof
#276Antibody Composition-Producing Cell
#277Cancer therapy using whole glucan particles and antibodies
#278Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof
#279Antibody composition-producing cell
#280Mammalian host cell modified by RNAi to inhibit α 1,6-fucosyltransferase
#281Antibody composition-producing cell
#282Antibody composition exhibiting increased cellular cytotoxicity due to glycosylation
#283Process for producing humanized chimera antibody
#284Process for producing humanized chimera antibody
#285Methods for producing antibody compositions with increased ADCC
#286Autophilic antibodies
#287Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
#288Method of modulating the activity of functional immune molecules
#289Method of modulating the activity of functional immune molecules
#290Antibody composition-producing cell
#291Cells of which genome is modified
#292Anti-cancer antibodies with reduced complement fixation
#293Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
#294Uses of monoclonal antibody 8H9
#295Novel ligand involved in the transmigration of leukocytes across the endothelium and uses therefor
#296Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
#297Therapeutic agent for patients having human FcgammaRIIIa